Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227001 · ClinicalTrials.gov registry record · Phase 1
A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza
A Phase 1 study of Influenza, Human, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 440
- Enrollment target
- 20
- Study locations
NCT05227001: Completed Phase 1 study of Influenza, Human, sponsored by Pfizer.
NCT05227001 is a Phase 1 study of Influenza, Human that has completed, run by Pfizer. The registered enrollment target is 440 participants, below the 16,199-participant average among 18 other Influenza, Human trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05227001, a Phase 1 study of Influenza, Human, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 440 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of the study vaccine for the potential prevention of influenza. The study vaccine is called Self-Amplifying Ribonucleic Acid vaccine (saRNA vaccine). This study is seeking participants who: * Are between the age of 18 to 49 years old. * Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * Are healthy as determined by medical history, physical examinations, and the study doctor. * For male participants, can father children and willing to use an acceptable method of contraception. Female participants who are not of childbearing potential; or male participant not able to father children. * Are capable of giving signed informed consent. Participants will receive either the saRNA vaccine, a licensed Influenza Vaccine (QIV) or a placebo. Participants will not know which vaccine they receive in advance. A placebo does not have any medicine in it but looks just like the study medicine. Participants will receive the study vaccines as a single shot in the arm. We will compare participant experiences to help us determine if the saRNA vaccine is safe and effective. Participants will take part in this study for 6 months. During this time, they will receive the study vaccine and participate in follow-up visits.
Primary Outcome
Pain at the injection site, redness, and swelling, as self-reported in electronic diaries.
Conditions Studied
Interventions
- BIOLOGICAL PF-07852352 Influenza saRNA 1
- BIOLOGICAL PF-07836391 Influenza saRNA
- BIOLOGICAL PF-07836394 Influenza saRNA
- BIOLOGICAL PF-07836395 Influenza saRNA
- BIOLOGICAL PF-07836396 Influenza saRNA
Study Locations (20)
Florida
- Finlay Medical Research - Greenacres City
- Advanced Pharma CR, LLC - Miami
- Miami Clinical Research - Miami
- Mount Sinai Hospital - Miami Beach
- Panax Clinical Research - Miami Lakes
- Pines Care Research Center, LLC - Pembroke Pines
- Pinnacle Health Care Center - Pembroke Pines
- Comprehensive Cardiology Consultants - Pembroke Pines
New York
- NYU Langone Health - New York
- SUNY Upstate Medical University Global Health Laboratory - Syracuse
- SUNY Upstate Medical University Institute for Global Health - Syracuse
- SUNY Upstate Medical University - Syracuse
Arizona
- Arizona Heart Rhythm Center - Phoenix
- Hope Research Institute - Phoenix
- The Pain Center of Arizona - Phoenix
Nebraska
- Pioneer Heart Institute - Lincoln
- Velocity Clinical Research, Omaha - Omaha
California
- Diablo Clinical Research, Inc. - Walnut Creek
Illinois
- Great Lakes Clinical Trials - Andersonville - Chicago
Ohio
- CTI Clinical Research Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2023-08-04 |
| Phase | Phase 1 |
What the finished NCT05227001 record still lists
NCT05227001 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, below the 16,199-participant average among 18 other Influenza, Human trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Influenza, Human appearing as the primary indexed condition, and to 5 interventions - of which PF-07852352 Influenza saRNA 1 is the first listed.
NCT05227001 names 20 study sites across 7 states, led by Florida, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT05227001 about?
NCT05227001 is a clinical study titled "A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza". The purpose of this clinical trial is to learn about the safety and effects of the study vaccine for the potential prevention of influenza. The study vaccine is called Self-Amplifying Ribonucleic Acid vaccine (saRNA vaccine). This study is seeking participants who: * Are between the age of 18 to 49...
What is the current status of trial NCT05227001?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 440 participants. The study started on 2022-04-28. Estimated completion is 2023-08-04.
What conditions does trial NCT05227001 study?
This clinical trial studies the following conditions: Influenza, Human.
What interventions are being tested in trial NCT05227001?
The interventions under investigation include: PF-07852352 Influenza saRNA 1 (BIOLOGICAL), PF-07836391 Influenza saRNA (BIOLOGICAL), PF-07836394 Influenza saRNA (BIOLOGICAL), PF-07836395 Influenza saRNA (BIOLOGICAL), PF-07836396 Influenza saRNA (BIOLOGICAL).
Who is sponsoring clinical trial NCT05227001?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05227001 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza, Human
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05227001's enrollment target sits among peer trials
440 12th of 18 higher than 7 of 18 other Influenza, Human trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza, Human trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
COMPLETED · Phase 1
-
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
RECRUITING · Phase 2
-
Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults
RECRUITING · Phase 4
-
Flu Infection at UPHS
RECRUITING
-
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI